BioVie Inc
Change company Symbol lookup
Select an option...
BIVI BioVie Inc
DOMH Dominari Holdings Inc
SMLR Semler Scientific Inc
GME GameStop Corp
DCO Ducommun Inc
QSI Quantum-Si Inc
TLS Telos Corp
ONB Old National Bancorp
TIG Trean Insurance Group Inc
NVDA NVIDIA Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Closing Price
$9.04
Day's Change
-1.16 (-11.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.22
Day's Low
9.00
Volume
(Light)
Volume:
409,201

10-day average volume:
552,547
409,201

Company Profile

BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
13.50x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

February 2023
Current Month
362.1K
Previous Month
389.8K
Percent of Float
3.25%
Days to Cover
0.8579 Days

Share Information

BIVI is in a share class of common stock
Float
7.0M
Shares Outstanding
35.0M
Institutions Holding Shares
39
3.76%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • James Lang
  • Cuong Viet DoPres.
  • Joanne Wendy KimCFO
  • Jonathan M. AdamsExec.VP
  • Clarence N. AhlemExec.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.